Pharming Group (NASDAQ:PHAR) Shares Up 1.2% - Time to Buy?

Key Points

• Pharming Group's stock price increased by 1.2% to $11.38, with a trading volume that was 8% lower than its average session volume.
• The company reported $0.06 earnings per share (EPS) for the last quarter, beating expectations of a loss and significantly increasing revenue to $93.20 million.
• Institutional investors have increased their stake in Pharming Group, with one firm purchasing 2,979 shares valued at approximately $32,000 recently.

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report)'s stock price traded up 1.2% during mid-day trading on Thursday . The company traded as high as $11.39 and last traded at $11.38. 10,143 shares were traded during mid-day trading, a decline of 8% from the average session volume of 11,056 shares. The stock had previously closed at $11.25.

Pharming Group Stock Up 0.7%

The business's 50 day moving average is $10.89 and its 200-day moving average is $9.68. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.07 and a current ratio of 2.79. The firm has a market capitalization of $854.59 million, a price-to-earnings ratio of -95.28 and a beta of 0.02.

Pharming Group (NASDAQ:PHAR - Get Free Report) last posted its earnings results on Thursday, July 31st. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.16. Pharming Group had a negative net margin of 2.19% and a negative return on equity of 3.31%. The business had revenue of $93.20 million for the quarter, compared to analyst estimates of $70.36 million. Pharming Group has set its FY 2025 guidance at EPS. Equities analysts anticipate that Pharming Group N.V. Sponsored ADR will post -0.2 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Pharming Group stock. EverSource Wealth Advisors LLC purchased a new stake in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,979 shares of the company's stock, valued at approximately $32,000. 0.03% of the stock is owned by institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.